Status:
COMPLETED
Comparison of Surgery Outcome Between Preoperative IVR and Intraoperative IVR in PPV for PDR
Lead Sponsor:
Peking University People's Hospital
Conditions:
Proliferative Diabetic Retinopathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Proliferative diabetic retinopathy (PDR) is the most common causes of irreversible blindness in diabetic retinopathy (DR).Intravitreal injection of anti-VEGF drugs is a good adjunct to vitreous surger...
Detailed Description
Proliferative diabetic retinopathy (PDR) is the most common causes of irreversible blindness in diabetic retinopathy (DR).It is characterized by progressive loss of vision, retinal edema, vitreous hem...
Eligibility Criteria
Inclusion
- patients aged 18 years or more with type 1 or 2 diabetes who were clinically diagnosed with PDR;
- persistent VH for more than 1 month or recurrent VH with or without panretinal photocoagulation (PRP);
- TRD detected by indirect ophthalmoscope or B-scan ultrasonography.
Exclusion
- previous vitrectomy or intravitreal injection in the study eyes;
- eyes with any ocular disease that may hinder visual improvement other than PDR, such as optic atrophy or macular hole;
- poor control of diabetes mellitus (DM) with hemoglobin A1c (HbA1c) \> 12%;
- history of thromboembolic events (including cerebral vascular infarctions or myocardial infarctions) or coagulation system disorders or receiving anticoagulant or antiplatelet therapy;
- eyes given gas tamponade or additional treatment during follow-up periods.
Key Trial Info
Start Date :
September 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 29 2022
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT05408416
Start Date
September 1 2021
End Date
May 29 2022
Last Update
June 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
People's Hospital of Peking University
Beijing, Beijing Municipality, China, 100044